{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:58:13Z","timestamp":1792429093193,"version":"4.5.0"},"reference-count":69,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"unspecified","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,3,7]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The Swedish InfCareHIV cohort was established in 2003 to ensure equal and effective care of people living with HIV (PLHIV) and enable long-term follow-up. InfCareHIV functions equally as a decision support system as a quality registry, ensuring up-to-date data reported in real time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>InfCareHIV includes data on &gt;99% of all people with diagnosed HIV in Sweden and up to now 13\u2009029 have been included in the cohort. InfCareHIV includes data on HIV-related biomarkers and antiretroviral therapies (ART) and also on demographics, patient-reported outcome measures and patient-reported experience measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings to date<\/jats:title>\n                    <jats:p>Sweden was in 2015 the first country to reach the UNAIDS (United Nations Programme on HIV\/AIDS)\/WHO\u2019s 90-90-90 goals. Late diagnosis of HIV infection was identified as a key problem in the Swedish HIV-epidemic, and low-level HIV viraemia while on ART associated with all-cause mortality. Increased HIV RNA load in the cerebrospinal fluid (CSF) despite suppression of the plasma viral load was found in 5% of PLHIV, a phenomenon referred to as \u2018CSF viral escape\u2019. Dolutegravir-based treatment in PLHIV with pre-existing nucleoside reverse transcriptase inhibitor-mutations was non-inferior to protease inhibitor-based regimens. An increase of transmitted drug resistance was observed in the InfCareHIV cohort. Lower efficacy for protease inhibitors was not due to lower adherence to treatment. Incidence of type 2 diabetes and insulin resistance was high in the ageing HIV population. Despite ART, the risk of infection-related cancer as well as lung cancer was increased in PLHIV compared with HIV-negative. PLHIV were less likely successfully treated for cervical precancer and more likely to have human papillomavirus types not included in current HPV vaccines. Self-reported sexual satisfaction in PLHIV is improving and is higher in women than men.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Future plans<\/jats:title>\n                    <jats:p>InfCareHIV provides a unique base to study and further improve long-term treatment outcomes, comorbidity management and health-related quality of life in people with HIV in Sweden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-069688","type":"journal-article","created":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T03:47:57Z","timestamp":1679197677000},"page":"e069688","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["Cohort profile: InfCareHIV, a prospective registry-based cohort study of people with diagnosed HIV in Sweden"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9962-5964","authenticated-orcid":false,"given":"Christina","family":"Carlander","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Br\u00e4nnstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden"},{"name":"Department of Infectious Diseases\/Venh\u00e4lsan, S\u00f6dersjukhuset, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"M\u00e5nsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Lund University, Infectious Diseases Research Unit, Malmo, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Elvstam","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Lund University, Lund, Sweden"},{"name":"Department of Infectious Diseases, V\u00e4xj\u00f6 Central Hospital, V\u00e4xj\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernilla","family":"Albinsson","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Blom","sequence":"additional","affiliation":[{"name":"HIV Sweden, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Mattsson","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Hovm\u00f6ller","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Sunderby Hospital, Lulea, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Norrgren","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Lund University Faculty of Science, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5sa","family":"Mellgren","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Svedhem","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Gissl\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg Sahlgrenska Academy, Gothenburg, Sweden"},{"name":"Department of Infectious Diseases, Region V\u00e4stra G\u00f6taland, Sahlgrenska University Hospital, Gothenbrug, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"S\u00f6nnerborg","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden"},{"name":"Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"key":"2025121514463776000_13.3.e069688.1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3018(17)30066-8"},{"key":"2025121514463776000_13.3.e069688.2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/apc.2018.0015","article-title":"Non-aids mortality is higher among successfully treated people living with HIV compared with matched HIV-negative control persons: a 15-year follow-up cohort study in Sweden","volume":"32","author":"de Coninck","year":"2018","journal-title":"AIDS Patient Care STDS"},{"key":"2025121514463776000_13.3.e069688.3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/QAD.0000000000002740","article-title":"High-throughput sequencing reveals a high prevalence of pretreatment HIV-1 drug resistance in Sweden","volume":"35","author":"Andersson","year":"2021","journal-title":"AIDS"},{"key":"2025121514463776000_13.3.e069688.4","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/infdis\/jiaa580","article-title":"Abnormal levels of some biomarkers of immune activation despite very early treatment of human immunodeficiency virus","volume":"223","author":"Schnittman","year":"2021","journal-title":"J Infect Dis"},{"key":"2025121514463776000_13.3.e069688.5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.20411\/pai.v5i1.365","article-title":"Pathogenesis of aging and age-related comorbidities in people with HIV: highlights from the HIV action workshop","volume":"5","author":"Gabuzda","year":"2020","journal-title":"Pathog Immun"},{"key":"2025121514463776000_13.3.e069688.6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/hiv.12321","article-title":"Deficiencies in the health care system contribute to a high rate of late HIV diagnosis in Sweden","volume":"17","author":"Br\u00e4nnstr\u00f6m","year":"2016","journal-title":"HIV Med"},{"key":"2025121514463776000_13.3.e069688.7","unstructured":"InfCareHIV . 2022. Available: https:\/\/infcarehiv.se [Accessed 24 Aug 2022]."},{"key":"2025121514463776000_13.3.e069688.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-016-0640-4","article-title":"Beyond viral suppression of HIV-the new quality of life frontier","volume":"14","author":"Lazarus","year":"2016","journal-title":"BMC Med"},{"key":"2025121514463776000_13.3.e069688.9","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/S2352-3018(14)70018-9","article-title":"Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population","volume":"1","author":"Miners","year":"2014","journal-title":"Lancet HIV"},{"key":"2025121514463776000_13.3.e069688.10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/hiv.12431","article-title":"Sweden, the first country to achieve the joint United nations programme on HIV\/AIDS (UNAIDS) \/World Health Organization (WHO) 90-90-90 continuum of HIV care targets","volume":"18","author":"Gissl\u00e9n","year":"2017","journal-title":"HIV Med"},{"key":"2025121514463776000_13.3.e069688.11","unstructured":"Commission E . European network of HIV\/AIDS cohort studies to coordinate at european and international level clinical research on HIV\/AIDS. 2015. Available: https:\/\/cordis.europa.eu\/project\/id\/260694 [Accessed 24 Aug 2022]."},{"key":"2025121514463776000_13.3.e069688.12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156916","article-title":"High concordance between self-reported adherence, treatment outcome and satisfaction with care using a nine-item health questionnaire in infcarehiv","volume":"11","author":"Marrone","year":"2016","journal-title":"PLoS One"},{"key":"2025121514463776000_13.3.e069688.13","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/S2352-3018(16)00023-0","article-title":"Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden","volume":"3","author":"H\u00e4ggblom","year":"2016","journal-title":"Lancet HIV"},{"key":"2025121514463776000_13.3.e069688.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242710","article-title":"Longitudinal trends and determinants of patient-reported side effects on ART-a Swedish national registry study","volume":"15","author":"Mellgren","year":"2020","journal-title":"PLoS One"},{"key":"2025121514463776000_13.3.e069688.15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12955-017-0691-z","article-title":"Development of a 12-item short version of the HIV stigma scale","volume":"15","author":"Reinius","year":"2017","journal-title":"Health Qual Life Outcomes"},{"key":"2025121514463776000_13.3.e069688.16","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-018-2041-5"},{"key":"2025121514463776000_13.3.e069688.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162503","article-title":"Symptomatic patients without epidemiological indicators of HIV have a high risk of missed diagnosis: a multi-centre cross sectional study","volume":"11","author":"Br\u00e4nnstr\u00f6m","year":"2016","journal-title":"PLoS One"},{"key":"2025121514463776000_13.3.e069688.18","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/hiv.12509","article-title":"A high rate of HIV-1 acquisition post immigration among migrants in Sweden determined by a CD4 T-cell decline trajectory model","volume":"18","author":"Br\u00e4nnstr\u00f6m","year":"2017","journal-title":"HIV Med"},{"key":"2025121514463776000_13.3.e069688.19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12955-015-0381-7","article-title":"Development and psychometric testing of a barriers to HIV testing scale among individuals with HIV infection in Sweden; the barriers to HIV testing scale-karolinska version","volume":"13","author":"Wiklander","year":"2015","journal-title":"Health Qual Life Outcomes"},{"key":"2025121514463776000_13.3.e069688.20","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1080\/09540121.2020.1844862","article-title":"Barriers to HIV testing as reported by individuals newly diagnosed with HIV infection in Sweden","volume":"33","author":"George-Svahn","year":"2021","journal-title":"AIDS Care"},{"key":"2025121514463776000_13.3.e069688.21","unstructured":"Government of Sweden . National strategy against HIV\/AIDS and certain other transmittable diseases. 2017. Available: www.regeringen.se\/4ad776\/globalassets\/regeringen\/dokument\/socialdepartementet\/fokhalsa-och-sjukvard\/nationell-strategi-mot-hiv-aids-och-vissa-andra-smittsamma-sjukdomar.pdf [Accessed 14 Feb 2023]."},{"key":"2025121514463776000_13.3.e069688.22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa413"},{"key":"2025121514463776000_13.3.e069688.23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180761","article-title":"Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment","volume":"12","author":"Elvstam","year":"2017","journal-title":"PLoS One"},{"key":"2025121514463776000_13.3.e069688.24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/hiv.12756","article-title":"Is low-level HIV-1 viraemia associated with elevated levels of markers of immune activation, coagulation and cardiovascular disease?","volume":"20","author":"Elvstam","year":"2019","journal-title":"HIV Med"},{"key":"2025121514463776000_13.3.e069688.25","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab131","article-title":"Associations between plasma human immunodeficiency virus (HIV) ribonucleic acid levels and incidence of invasive cancer in people with HIV after initiation of combination antiretroviral therapy","volume":"8","author":"Elvstam","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025121514463776000_13.3.e069688.26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0268540","article-title":"Factors associated with low-level viraemia in people with HIV starting antiretroviral therapy: a Swedish observational study","volume":"17","author":"Brattg\u00e5rd","year":"2022","journal-title":"PLoS One"},{"key":"2025121514463776000_13.3.e069688.27","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1097\/QAD.0000000000003240","article-title":"Associations between HIV viremia during antiretroviral therapy and cardiovascular disease","volume":"36","author":"Elvstam","year":"2022","journal-title":"AIDS"},{"key":"2025121514463776000_13.3.e069688.28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/QAD.0000000000003117","article-title":"Failure to restore CD4+ cell count associated with infection-related and noninfection-related cancer","volume":"36","author":"Malmstr\u00f6m","year":"2022","journal-title":"AIDS"},{"key":"2025121514463776000_13.3.e069688.29","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1097\/QAD.0000000000001853","article-title":"Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia","volume":"32","author":"Carlander","year":"2018","journal-title":"AIDS"},{"key":"2025121514463776000_13.3.e069688.30","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/ijc.30188","article-title":"Impact of immunosuppression and region of birth on risk of cervical intraepithelial neoplasia among migrants living with HIV in Sweden","volume":"139","author":"Carlander","year":"2016","journal-title":"Int J Cancer"},{"key":"2025121514463776000_13.3.e069688.31","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-20-0969"},{"key":"2025121514463776000_13.3.e069688.32","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1097\/QAD.0000000000003026","article-title":"Nonvaccine human papillomavirus genotype common in women with HIV failing cervical precancer treatment","volume":"35","author":"Carlander","year":"2021","journal-title":"AIDS"},{"key":"2025121514463776000_13.3.e069688.33","unstructured":"Cancercentrum . Prevention of cervical cancer. National health guidelines; 2022. Available: https:\/\/cancercentrum.se\/globalassets\/vara-uppdrag\/prevention-tidig-upptackt\/gynekologisk-cellprovskontroll\/vardprogram\/nationellt-vardprogram-cervixcancerprevention.pdf [Accessed 14 Feb 2023]."},{"key":"2025121514463776000_13.3.e069688.34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254079","article-title":"Development of type 2 diabetes and insulin resistance in people with HIV infection: prevalence, incidence and associated factors","volume":"16","author":"Bratt","year":"2021","journal-title":"PLoS One"},{"key":"2025121514463776000_13.3.e069688.35","unstructured":"M\u00f6ller I , Gissl\u00e9n M , Wagner P , et al . Clinical outcome in people with COVID-19 by HIV-status: a nationwide register study. CROI 2022."},{"key":"2025121514463776000_13.3.e069688.36","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/cid\/ciab943","article-title":"Cerebrospinal fluid viral load across the spectrum of untreated human immunodeficiency virus type 1 (HIV-1) infection: a cross-sectional multicenter study","volume":"75","author":"Ulfhammer","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025121514463776000_13.3.e069688.37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236162","article-title":"Herpes zoster in HIV-1 infection: the role of CSF pleocytosis in secondary CSF escape and discordance","volume":"15","author":"Hagberg","year":"2020","journal-title":"PLoS One"},{"key":"2025121514463776000_13.3.e069688.38","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/cid\/ciy1066","article-title":"Human immunodeficiency virus type 1 RNA detected in the central nervous system (CNS) after years of suppressive antiretroviral therapy can originate from a replicating CNS reservoir or clonally expanded cells","volume":"69","author":"Joseph","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025121514463776000_13.3.e069688.39","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001950"},{"key":"2025121514463776000_13.3.e069688.40","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix662"},{"key":"2025121514463776000_13.3.e069688.41","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw454"},{"key":"2025121514463776000_13.3.e069688.42","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-10-62","article-title":"Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy","volume":"10","author":"Yilmaz","year":"2013","journal-title":"J Neuroinflammation"},{"key":"2025121514463776000_13.3.e069688.43","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-021-02527-8","article-title":"Effect of antiretroviral treatment on blood-brain barrier integrity in HIV-1 infection","volume":"21","author":"Anesten","year":"2021","journal-title":"BMC Neurol"},{"key":"2025121514463776000_13.3.e069688.44","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1080\/23744235.2019.1670352","article-title":"Switching from a regimen containing abacavir\/lamivudine or emtricitabine\/tenofovir disoproxil fumarate to emtricitabine\/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection","volume":"51","author":"Yilmaz","year":"2019","journal-title":"Infect Dis (Lond)"},{"key":"2025121514463776000_13.3.e069688.45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0250987","article-title":"Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression","volume":"16","author":"Gisslen","year":"2021","journal-title":"PLoS One"},{"key":"2025121514463776000_13.3.e069688.46","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-019-1404-9","article-title":"Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection","volume":"16","author":"Hermansson","year":"2019","journal-title":"J Neuroinflammation"},{"key":"2025121514463776000_13.3.e069688.47","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11904-019-00420-1","article-title":"Cerebrospinal fluid concentrations of the synaptic marker neurogranin in neuro-HIV and other neurological disorders","volume":"16","author":"Yilmaz","year":"2019","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2025121514463776000_13.3.e069688.48","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000512","article-title":"CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection","volume":"6","author":"Gissl\u00e9n","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025121514463776000_13.3.e069688.49","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000300","article-title":"Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV","volume":"3","author":"Anesten","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025121514463776000_13.3.e069688.50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158973","article-title":"Association between plasma homocysteine levels and neuronal injury in HIV infection","volume":"11","author":"Ahlgren","year":"2016","journal-title":"PLoS One"},{"key":"2025121514463776000_13.3.e069688.51","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/21505594.2016.1212155","article-title":"No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau)","volume":"8","author":"Krut","year":"2017","journal-title":"Virulence"},{"key":"2025121514463776000_13.3.e069688.52","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ebiom.2015.11.036","article-title":"Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study","volume":"3","author":"Gissl\u00e9n","year":"2016","journal-title":"EBioMedicine"},{"key":"2025121514463776000_13.3.e069688.53","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1097\/QAI.0000000000000873","article-title":"Reduced baseline sensitivity to maraviroc inhibition among R5 HIV-1 isolates from individuals with severe immunodeficiency","volume":"71","author":"Karlsson","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025121514463776000_13.3.e069688.54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088591","article-title":"Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients","volume":"9","author":"Jessen Krut","year":"2014","journal-title":"PLoS One"},{"key":"2025121514463776000_13.3.e069688.55","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-199908010-00003"},{"key":"2025121514463776000_13.3.e069688.56","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/135965350501000607","article-title":"Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment","volume":"10","author":"Mellgren","year":"2005","journal-title":"Antivir Ther"},{"key":"2025121514463776000_13.3.e069688.57","doi-asserted-by":"publisher","DOI":"10.1086\/657342"},{"key":"2025121514463776000_13.3.e069688.58","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1628-6"},{"key":"2025121514463776000_13.3.e069688.59","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1093\/infdis\/jiz031","article-title":"Antiretroviral treatment of acute HIV infection normalizes levels of cerebrospinal fluid markers of central nervous system (CNS) inflammation: a consequence of a reduced CNS reservoir?","volume":"220","author":"Gissl\u00e9n","year":"2019","journal-title":"J Infect Dis"},{"key":"2025121514463776000_13.3.e069688.60","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3389\/fimmu.2018.00019","article-title":"Human immunodeficiency virus type-1 elite controllers maintain low co-expression of inhibitory receptors on CD4+ T cells","volume":"9","author":"Noyan","year":"2018","journal-title":"Front Immunol"},{"key":"2025121514463776000_13.3.e069688.61","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103607","article-title":"Integrative proteo-transcriptomic and immunophenotyping signatures of HIV-1 elite control phenotype: a cross-talk between glycolysis and HIF signaling","volume":"25","author":"Akusj\u00e4rvi","year":"2022","journal-title":"IScience"},{"key":"2025121514463776000_13.3.e069688.62","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40121-022-00626-8","article-title":"Novel naturally occurring dipeptides and single-stranded oligonucleotide act as entry inhibitors and exhibit a strong synergistic anti-HIV-1 profile","volume":"11","author":"Ce\u00f1a-Diez","year":"2022","journal-title":"Infect Dis Ther"},{"key":"2025121514463776000_13.3.e069688.63","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-06860-2","article-title":"Recent increased identification and transmission of HIV-1 unique recombinant forms in Sweden","volume":"7","author":"Neogi","year":"2017","journal-title":"Sci Rep"},{"key":"2025121514463776000_13.3.e069688.64","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ijantimicag.2018.01.009","article-title":"Effect of dolutegravir in combination with nucleoside reverse transcriptase inhibitors (nrtis) on people living with HIV who have pre-existing NRTI mutations","volume":"51","author":"S\u00f6rstedt","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2025121514463776000_13.3.e069688.65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246171","article-title":"Higher plasma drug levels in elderly people living with HIV treated with darunavir","volume":"16","author":"Tyrberg","year":"2021","journal-title":"PLoS One"},{"key":"2025121514463776000_13.3.e069688.66","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/09540121.2021.1909698","article-title":"People living with HIV in Sweden report high levels of sexual satisfaction in a registry-based cohort study","volume":"34","author":"Carlsson-Lalloo","year":"2022","journal-title":"AIDS Care"},{"key":"2025121514463776000_13.3.e069688.67","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/09564624221100056","article-title":"Sexual satisfaction and its associations with patient-reported outcomes in a cohort of women living with human immunodeficiency virus in Sweden","volume":"33","author":"Carlsson-Lalloo","year":"2022","journal-title":"Int J STD AIDS"},{"key":"2025121514463776000_13.3.e069688.68","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/QAD.0000000000002724","article-title":"Employment by HIV status, mode of HIV transmission and migrant status: a nation-wide population-based study","volume":"35","author":"Carlander","year":"2021","journal-title":"AIDS"},{"key":"2025121514463776000_13.3.e069688.69","unstructured":"Regioner SKo . Certifieringsniv\u00e5. 2022. Available: https:\/\/skr.se\/kvalitetsregister\/hittaregister\/certifieringsnivaer\/certifieringsniva1.43960.html [Accessed 24 Aug 2022]."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-069688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T22:46:50Z","timestamp":1765838810000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-069688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":69,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,17]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/bmjopen-2022-069688"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-069688","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}